FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018581695> ?p ?o ?g. }

• W2018581695 endingPage "112" @default.
• W2018581695 startingPage "104" @default.
• W2018581695 abstract "The cervix is an ideal organ for chemoprevetion studies and the study of squamous carcinogenesis. In chemoprevention trial design, four factors are important: high-risk cohorts must be identified; suitable agents must be selected; study designs should include Phase I, II and III; and studies should include the use of surrogate endpoint biomarkers. High-risk cohorts can be selected for Phase I, II and III trial in the cervix, for example, patients with high grade lesion such as cervical interaepithelial neoplasia (CIN) grade 3 and carcinoma in situ (CIS). A Phase III trial might also include patients with lesions infected with ocogenic HPV types. The cervix is accessible and can be safely followed with Papanicolaou (Pap) smears and colposcopy. Suitable agents include those likely to work in squamous lesions, including retinoids, difluoromethylornithine β-carotene, and others. In Phase I chemopreventive studies, does are de-escalated rather than escalated, determining toxicity and optimal dose schedule. Phase II studies looking at effectiveness need placebo control groups since regression of high-risk lesions is possible. Phase III studies, now multicenteric, should be carefully designed and include wide patient representation in order to evaluate the risk-benefit ratio of therpy, focusing on cancer incidence reduction. Surrogate endpoint biomarkers include quantitative histopathology, biologic measures of histopathologic markers include nuclear grading (i.e., shape, area, optical density, texture), nuclear pleomerphism, ploidy, and nucleolar size and position. Biomarkers under study at the present time in the cervix include proliferation markers (PCNA), regulation markers (EGFR, ras, myc, p53, retinoic acid receptors, ODC, spermidine/spermine ratios), differentiation markers (involucrin, cornifin, keratins), and markers of genetic instability (chromosome polysomy). Fluorescent spectroscopy uses light to probe the biochemical properties of tissue. This technique provides an automated diagnosis in real time with comparable sensitivity and specificity to colposcopy and can be used to monitor lesions in chemoprevention trials. Recruitment designs for cervix studies need to include a large referral population and patients with sufficiently large lesions. Clinicians involved in such studies need to stress contraception and smoking cessation, deal with language barriers, and provide compensation for child care and parking to patients in order to increase compliance." @default.
• W2018581695 created "2016-06-24" @default.
• W2018581695 creator A5012676999 @default.
• W2018581695 creator A5016125241 @default.
• W2018581695 creator A5020196351 @default.
• W2018581695 creator A5064117402 @default.
• W2018581695 creator A5071615283 @default.
• W2018581695 creator A5073876235 @default.
• W2018581695 creator A5085188591 @default.
• W2018581695 date "1995-01-01" @default.
• W2018581695 modified "2023-10-17" @default.
• W2018581695 title "Chemoprvention traials in the cervix: Design, feasibility, and recruitment" @default.
• W2018581695 cites W1644015069 @default.
• W2018581695 cites W1969221366 @default.
• W2018581695 cites W1972296400 @default.
• W2018581695 cites W2002946843 @default.
• W2018581695 cites W2012603529 @default.
• W2018581695 cites W2052369736 @default.
• W2018581695 cites W2053807011 @default.
• W2018581695 cites W2056880228 @default.
• W2018581695 cites W2058162403 @default.
• W2018581695 cites W2070533822 @default.
• W2018581695 cites W2075905051 @default.
• W2018581695 cites W2114784597 @default.
• W2018581695 cites W2127053561 @default.
• W2018581695 cites W2128737857 @default.
• W2018581695 cites W2168184048 @default.
• W2018581695 cites W2326564306 @default.
• W2018581695 cites W2337028134 @default.
• W2018581695 cites W2403313181 @default.
• W2018581695 cites W3128343078 @default.
• W2018581695 cites W4249586256 @default.
• W2018581695 cites W4361868650 @default.
• W2018581695 doi "https://doi.org/10.1002/jcb.240590914" @default.
• W2018581695 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8747384" @default.
• W2018581695 hasPublicationYear "1995" @default.
• W2018581695 type Work @default.
• W2018581695 sameAs 2018581695 @default.
• W2018581695 citedByCount "20" @default.
• W2018581695 countsByYear W20185816952012 @default.
• W2018581695 countsByYear W20185816952013 @default.
• W2018581695 crossrefType "journal-article" @default.
• W2018581695 hasAuthorship W2018581695A5012676999 @default.
• W2018581695 hasAuthorship W2018581695A5016125241 @default.
• W2018581695 hasAuthorship W2018581695A5020196351 @default.
• W2018581695 hasAuthorship W2018581695A5064117402 @default.
• W2018581695 hasAuthorship W2018581695A5071615283 @default.
• W2018581695 hasAuthorship W2018581695A5073876235 @default.
• W2018581695 hasAuthorship W2018581695A5085188591 @default.
• W2018581695 hasConcept C121608353 @default.
• W2018581695 hasConcept C126322002 @default.
• W2018581695 hasConcept C141341695 @default.
• W2018581695 hasConcept C142724271 @default.
• W2018581695 hasConcept C143998085 @default.
• W2018581695 hasConcept C203092338 @default.
• W2018581695 hasConcept C2777343196 @default.
• W2018581695 hasConcept C2777740455 @default.
• W2018581695 hasConcept C2778220009 @default.
• W2018581695 hasConcept C2778981785 @default.
• W2018581695 hasConcept C529295009 @default.
• W2018581695 hasConcept C535046627 @default.
• W2018581695 hasConcept C71924100 @default.
• W2018581695 hasConceptScore W2018581695C121608353 @default.
• W2018581695 hasConceptScore W2018581695C126322002 @default.
• W2018581695 hasConceptScore W2018581695C141341695 @default.
• W2018581695 hasConceptScore W2018581695C142724271 @default.
• W2018581695 hasConceptScore W2018581695C143998085 @default.
• W2018581695 hasConceptScore W2018581695C203092338 @default.
• W2018581695 hasConceptScore W2018581695C2777343196 @default.
• W2018581695 hasConceptScore W2018581695C2777740455 @default.
• W2018581695 hasConceptScore W2018581695C2778220009 @default.
• W2018581695 hasConceptScore W2018581695C2778981785 @default.
• W2018581695 hasConceptScore W2018581695C529295009 @default.
• W2018581695 hasConceptScore W2018581695C535046627 @default.
• W2018581695 hasConceptScore W2018581695C71924100 @default.
• W2018581695 hasIssue "S23" @default.
• W2018581695 hasLocation W20185816951 @default.
• W2018581695 hasLocation W20185816952 @default.
• W2018581695 hasOpenAccess W2018581695 @default.
• W2018581695 hasPrimaryLocation W20185816951 @default.
• W2018581695 hasRelatedWork W1852785632 @default.
• W2018581695 hasRelatedWork W2093565530 @default.
• W2018581695 hasRelatedWork W2169374891 @default.
• W2018581695 hasRelatedWork W2297790284 @default.
• W2018581695 hasRelatedWork W2514884906 @default.
• W2018581695 hasRelatedWork W2611353607 @default.
• W2018581695 hasRelatedWork W3025555446 @default.
• W2018581695 hasRelatedWork W3080304190 @default.
• W2018581695 hasRelatedWork W3089163820 @default.
• W2018581695 hasRelatedWork W4289348819 @default.
• W2018581695 hasVolume "59" @default.
• W2018581695 isParatext "false" @default.
• W2018581695 isRetracted "false" @default.
• W2018581695 magId "2018581695" @default.
• W2018581695 workType "article" @default.